HC Wainwright Estimates Acelyrin’s Q1 Earnings (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acelyrin in a research report issued to clients and investors on Tuesday, January 7th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.44) per share for the quarter. HC Wainwright has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

Several other brokerages also recently commented on SLRN. Wells Fargo & Company reduced their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Citigroup reduced their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Acelyrin presently has a consensus rating of “Hold” and a consensus price target of $9.60.

Acelyrin Stock Down 3.7 %

Shares of NASDAQ SLRN opened at $2.06 on Thursday. Acelyrin has a 12 month low of $1.91 and a 12 month high of $8.89. The company has a market cap of $206.67 million, a price-to-earnings ratio of -0.84 and a beta of 1.94. The business has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $4.83.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Acelyrin by 30.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after purchasing an additional 388,631 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Acelyrin during the 2nd quarter valued at about $590,000. Point72 Asset Management L.P. increased its holdings in shares of Acelyrin by 566.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock valued at $1,234,000 after acquiring an additional 212,758 shares during the last quarter. Almitas Capital LLC acquired a new position in shares of Acelyrin during the 2nd quarter valued at about $1,659,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Acelyrin by 81.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock valued at $3,006,000 after acquiring an additional 273,604 shares during the last quarter. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.